Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.63 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.63 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.63 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.63 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.63 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.63 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.63 |
| ▸ | PLA2G2A | P14555 | 2/20 | 0.51 |
| ▸ | NPC1 | O15118 | 5/20 | 0.50 |
| ▸ | RAB9A | P51151 | 5/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.50 |
| ▸ | MEN1 | O00255 | 3/20 | 0.50 |
| ▸ | CASP3 | P42574 | 1/20 | 0.50 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.50 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.50 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | USP2 | O75604 | 2/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4392160 | 0.88 | NPC1 (0.53) | KDM4ESLC6A4SLC6A3CYP1A2CYP2D6 | |
| SCHEMBL23354126 | 0.87 | SLC6A3 (0.71) | KDM4ESLC6A4SLC6A3CYP1A2CYP2D6 | |
| SCHEMBL31676847 | 0.87 | SLC6A3 (0.71) | KDM4ESLC6A4SLC6A3CYP1A2CYP2D6 | |
| SCHEMBL6778891 | 0.86 | SMN1; SMN2 (0.62) | KDM4ESLC6A4SLC6A3CYP1A2CYP2D6 | |
| SCHEMBL6775841 | 0.84 | KDM4E (0.62) | KDM4ESLC6A4SLC6A3CYP1A2CYP2D6 | |
| SCHEMBL6701426 | 0.84 | KDM4E (0.58) | KDM4ESLC6A4SLC6A3CYP1A2CYP2D6 | |
| Hydrochloric Acid SCHEMBL5797609 | 0.84 | SMN1; SMN2 (0.48) | KDM4ESLC6A4SLC6A3CYP1A2CYP2D6 | |
| SCHEMBL2949877 | 0.84 | KDM4E (0.64) | KDM4ESLC6A4SLC6A3CYP1A2CYP2D6 | |
| SCHEMBL7249446 | 0.83 | SLC6A3 (0.65) | KDM4ESLC6A4SLC6A3CYP1A2CYP2D6 | |
| SCHEMBL7563000 | 0.83 | SLC6A3 (0.65) | KDM4ESLC6A4SLC6A3CYP1A2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6777438-B2 | TREATING A DISEASE OR MEDICAL CONDITION MEDIATED THROUGH FARNESYLATION OF RAS BY FARNESYL TRANSFERASE | ASTRAZENECA AB (SE) | 2004-08-17 | — | — | US | disclosed |
| US-20030096842-A1 | Inhibitors of farnesyl protein transferase | ASTRAZENECA AB (SE) | 2003-05-22 | — | — | US | disclosed |
| EP-1242372-A1 | INHIBITORS OF FARNESYL PROTEIN TRANSFERASE | AstraZeneca AB (SE) | 2002-09-25 | — | — | EP | disclosed |
| US-20020058665-A1 | Imidazole derivatives and their use as farnesyl protein transferase inhibitors | ASTRAZENECA UK LIMITED | 2002-05-16 | — | — | US | disclosed |
| US-20020052376-A1 | Imidazole derivatives and their use as farnesyl protein transferase inhibitors | ASTRAZENECA UK LIMITED | 2002-05-02 | — | — | US | disclosed |
| US-6342765-B1 | COMPOUNDS THAT INHIBIT FARNESYLATION OF MUTANT RAS GENE PRODUCTS; TREATING DISEASES, ESPECIALLY CANCER, WHICH ARE MEDIATED THROUGH FARNESYLATION OF RAS | ASTRAZENECA UK LIMITED (GB) | 2002-01-29 | — | — | US | disclosed |
| EP-1025088-B1 | IMIDAZOLE DERIVATIVES AND THEIR USE AS FARNESYL PROTEIN TRANSFERASE INHIBITORS | ASTRAZENECA AB (SE) | 2001-09-05 | — | — | EP | disclosed |
| WO-2001046138-A1 | INHIBITORS OF FARNESYL PROTEIN TRANSFERASE | ASTRAZENECA AB (SE) | 2001-06-28 | — | — | WO | disclosed |
| EP-1025088-A1 | IMIDAZOLE DERIVATIVES AND THEIR USE AS FARNESYL PROTEIN TRANSFERASE INHIBITORS | AstraZeneca UK Limited (GB) | 2000-08-09 | — | — | EP | disclosed |
| WO-1999020611-A1 | IMIDAZOLE DERIVATIVES AND THEIR USE AS FARNESYL PROTEIN TRANSFERASE INHIBITORS | ZENECA LIMITED (GB) | 1999-04-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020058665-A1 | Imidazole derivatives and their use as farnesyl protein transferase inhibitors | FNTA, FNTB, RABGGTA | KDM4E 3060/4885SLC6A4 4443/4885SLC6A3 4218/4885 |
| US-20020052376-A1 | Imidazole derivatives and their use as farnesyl protein transferase inhibitors | FNTA, FNTB, RABGGTA | KDM4E 3247/4885SLC6A4 4620/4885SLC6A3 4445/4885 |
| US-20030096842-A1 | Inhibitors of farnesyl protein transferase | FNTA, FNTB, FDPS | KDM4E 2119/4885SLC6A4 4364/4885SLC6A3 4614/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.